Fred C G J Sweep

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7709266/publications.pdf

Version: 2024-02-01

445 papers

31,423 citations

75 h-index 158 g-index

458 all docs

458 docs citations

458 times ranked

48215 citing authors

#	Article	IF	CITATIONS
1	Production of 11-Oxygenated Androgens by Testicular Adrenal Rest Tumors. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e272-e280.	3.6	12
2	Diurnal salivary androstenedione and 17â€hydroxyprogesterone levels in healthy volunteers for monitoring treatment efficacy of patients with congenital adrenal hyperplasia. Clinical Endocrinology, 2022, 97, 36-42.	2.4	8
3	Optimizing the Timing of Highest Hydrocortisone Dose in Children and Adolescents With 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1661-e1672.	3.6	5
4	Immune cell composition in the endometrium of patients with a complete molar pregnancy: Effects on outcome. Gynecologic Oncology, 2021, 160, 450-456.	1.4	4
5	Conditioning cortisol in healthy young women – A randomized controlled trial. Psychoneuroendocrinology, 2021, 124, 105081.	2.7	5
6	Quality of Life in Men With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. Frontiers in Endocrinology, 2021, 12, 626646.	3.5	8
7	Production of 11-Oxygenated Androgens by Testicular Adrenal Rest Tumors. Journal of the Endocrine Society, 2021, 5, A814-A815.	0.2	0
8	Harmonization of LC-MS/MS Measurements of Plasma Free Normetanephrine, Metanephrine, and 3-Methoxytyramine. Clinical Chemistry, 2021, 67, 1098-1112.	3.2	20
9	Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement. Gynecologic Oncology, 2021, 163, 531-537.	1.4	2
10	A tutorial on dynamic risk prediction of a binary outcome based on a longitudinal biomarker. Biometrical Journal, 2020, 62, 398-413.	1.0	5
11	Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1725-1735.	2.5	6
12	Changes in DNA Damage Repair Gene Expression and Cell Cycle Gene Expression Do Not Explain Radioresistance in Tamoxifen-Resistant Breast Cancer. Oncology Research, 2020, 28, 33-40.	1.5	12
13	The circular RNome of primary breast cancer. Genome Research, 2019, 29, 356-366.	5 . 5	85
14	Testicular Adrenal Rest Tumors: Current Insights on Prevalence, Characteristics, Origin, and Treatment. Endocrine Reviews, 2019, 40, 973-987.	20.1	92
15	Ultrafine particles and ozone perturb norepinephrine clearance rather than centrally generated sympathetic activity in humans. Scientific Reports, 2019, 9, 3641.	3.3	15
16	HE4 is superior to CA125 in the detection of recurrent disease in the follow-up of high risk endometrial cancer patients. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 234, e117.	1.1	1
17	HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients. Tumor Biology, 2018, 40, 101042831875710.	1.8	36
18	Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer. Clinical Cancer Research, 2018, 24, 3397-3408.	7.0	68

#	Article	IF	CITATIONS
19	Gonadal function in adult male patients with congenital adrenal hyperplasia. European Journal of Endocrinology, 2018, 178, 285-294.	3.7	57
20	The macrophage migration inhibitory factor pathway in human B cells is tightly controlled and dysregulated in multiple sclerosis. European Journal of Immunology, 2018, 48, 1861-1871.	2.9	22
21	Human Pharmacological Conditioning of the Immune and Endocrine System: Challenges and Opportunities. International Review of Neurobiology, 2018, 138, 61-80.	2.0	12
22	Procollagenâ€3 N â€terminal peptide measurements for the detection of liver fibrosis in methotrexateâ€treated patients with psoriasis: daily practice use and clinical implications. British Journal of Dermatology, 2017, 177, 1454-1457.	1.5	6
23	Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset. Annals of Oncology, 2017, 28, 1856-1861.	1.2	21
24	Bilateral Testicular Tumors Resulting in Recurrent Cushing Disease After Bilateral Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 339-344.	3.6	19
25	Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer. Scientific Reports, 2017, 7, 2099.	3.3	33
26	The added value of hysterectomy in the management of gestational trophoblastic neoplasia. Gynecologic Oncology, 2017, 145, 536-542.	1.4	23
27	Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment. Clinical Pharmacology and Therapeutics, 2017, 102, 671-678.	4.7	38
28	GATA transcription factors in testicular adrenal rest tumours. Endocrine Connections, 2017, 6, 866-875.	1.9	14
29	Serum Human Chorionic Gonadotropin Normogram for the Detection of Gestational Trophoblastic Neoplasia. International Journal of Gynecological Cancer, 2017, 27, 1035-1041.	2.5	8
30	Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer. Biological Chemistry, 2017, 398, 1151-1164.	2.5	17
31	Cardiovascular and metabolic risk in pediatric patients with congenital adrenal hyperplasia due to 21 hydroxylase deficiency. Journal of Pediatric Endocrinology and Metabolism, 2017, 30, 957-966.	0.9	23
32	Plasma Levels of Macrophage Migration Inhibitory Factor and d-Dopachrome Tautomerase Show a Highly Specific Profile in Early Life. Frontiers in Immunology, 2017, 8, 26.	4.8	29
33	Meta-GWAS and Meta-Analysis of Exome Array Studies Do Not Reveal Genetic Determinants of Serum Hepcidin. PLoS ONE, 2016, 11, e0166628.	2.5	2
34	Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes and Endocrinology, the, 2016, 4, 739-746.	11.4	208
35	The influence of lung metastases on the clinical course of gestational trophoblastic neoplasia: a historical cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1839-1845.	2.3	18
36	Pharmacokinetics and pharmacodynamics of eculizumab in individualized treatment of atypical hemolytic uremic syndrome. Immunobiology, 2016, 221, 1141.	1.9	1

#	Article	IF	CITATIONS
37	PO-0997: Interferon response genes in breast cancer resistance to endocrine treatment and radiotherapy. Radiotherapy and Oncology, 2016, 119, S484.	0.6	O
38	Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients. Scientific Reports, 2016, 6, 32027.	3. 3	19
39	Differential Effects of Environmental and Genetic Factors on T and B Cell Immune Traits. Cell Reports, 2016, 17, 2474-2487.	6.4	154
40	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Science Advances, 2016, 2, e1601737.	10.3	175
41	Host and Environmental Factors Influencing Individual Human Cytokine Responses. Cell, 2016, 167, 1111-1124.e13.	28.9	364
42	Dutch Risk Classification and FIGO 2000 for Gestational Trophoblastic Neoplasia Compared. International Journal of Gynecological Cancer, 2016, 26, 1712-1716.	2.5	10
43	Do blood plasma levels of oxytocin moderate the effect of nasally administered oxytocin on social orienting in high-functioning male adults with autism spectrum disorder?. Psychopharmacology, 2016, 233, 2737-2751.	3.1	23
44	Evaluation of the highly sensitive Roche thyroglobulin II assay and establishment of a reference limit for thyroglobulin-negative patient samples. Practical Laboratory Medicine, 2016, 5, 6-13.	1.3	12
45	Preserved Autonomic Cardiovascular Regulation With Cardiac Pacemaker Inhibition: A Crossover Trial Using Highâ€Fidelity Cardiovascular Phenotyping. Journal of the American Heart Association, 2016, 5, .	3.7	7
46	Trends in incidence for gestational trophoblastic disease over the last 20years in a population-based study. Gynecologic Oncology, 2016, 140, 70-75.	1.4	49
47	Empathic accuracy and oxytocin after tryptophan depletion in adults at risk for depression. Psychopharmacology, 2016, 233, 111-120.	3.1	16
48	High expression levels of macrophage migration inhibitory factor sustain the innate immune responses of neonates. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E997-1005.	7.1	67
49	Cortisol levels of infants in center care across the first year of life: links with quality of care and infant temperament. Stress, 2016, 19, 8-17.	1.8	19
50	Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera. Journal of Proteome Research, 2016, 15, 1230-1242.	3.7	21
51	4â€protein signature predicting tamoxifen treatment outcome in recurrent breast cancer. Molecular Oncology, 2016, 10, 24-39.	4.6	31
52	Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer. Oncotarget, 2016, 7, 3098-3110.	1.8	26
53	Abstract S4-07: Tamoxifen resistance driven by the DNA cytosine deaminase APOBEC3B in recurrent estrogen receptor positive breast cancer. Cancer Research, 2016, 76, S4-07-S4-07.	0.9	1
54	Hypoxic regulation of the PERK/ATF4/LAMP3â€arm of the unfolded protein response in head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 896-905.	2.0	28

#	Article	IF	CITATIONS
55	Salivary morning androstenedione and 17î±-OH progesterone levels in childhood and puberty in patients with classic congenital adrenal hyperplasia. Clinical Chemistry and Laboratory Medicine, 2015, 53, 461-8.	2.3	15
56	Poor prognosis of constitutive \hat{I}^3 -H2AX expressing triple-negative breast cancers is associated with telomere length. Biomarkers in Medicine, 2015, 9, 383-390.	1.4	17
57	Molecular Characterization of Testicular Adrenal Rest Tumors in Congenital Adrenal Hyperplasia: Lesions With Both Adrenocortical and Leydig Cell Features. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E524-E530.	3.6	59
58	Genotype-Specific Differences in the Tumor Metabolite Profile of Pheochromocytoma and Paraganglioma Using Untargeted and Targeted Metabolomics. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E214-E222.	3 . 6	33
59	Thyrotropin Versus Age Relation as an Indicator of Historical Iodine Intake. Thyroid, 2015, 25, 629-634.	4.5	29
60	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome Research, 2015, 25, 814-824.	5 . 5	69
61	Adrenal Steroid Metabolites Accumulating in Congenital Adrenal Hyperplasia Lead to Transactivation of the Glucocorticoid Receptor. Endocrinology, 2015, 156, 3504-3510.	2.8	32
62	Serum GDF15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain, but Not to Disease Progression in Adult m.3243A>G Carriers. JIMD Reports, 2015, 24, 69-81.	1.5	39
63	Improved metastasis-free survival in nonadjuvantly treated postmenopausal breast cancer patients with chemokine receptor 5 del32 frameshift mutations. International Journal of Cancer, 2015, 136, 91-97.	5.1	16
64	Therapeutic targeting of autophagy in cancer. Part I: Molecular pathways controlling autophagy. Seminars in Cancer Biology, 2015, 31, 89-98.	9.6	47
65	Dutasteride and Enzalutamide Synergistically Suppress Prostate Tumor Cell Proliferation. Journal of Urology, 2015, 193, 1023-1029.	0.4	15
66	An LCâ€"MS/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism. Journal of Steroid Biochemistry and Molecular Biology, 2015, 145, 75-84.	2.5	129
67	Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy. Seminars in Cancer Biology, 2015, 31, 99-105.	9.6	69
68	Abstract LB-118: High APOBEC3B mRNA levels in estrogen receptor-positive primary tumors predict short time to progression for hormone-naive breast cancer patients treated with 1st line tamoxifen., 2015,,.		0
69	Processed pseudogenes acquired somatically during cancer development. Nature Communications, 2014, 5, 3644.	12.8	86
70	Identification of Novel Genetic Loci Associated with Thyroid Peroxidase Antibodies and Clinical Thyroid Disease. PLoS Genetics, 2014, 10, e1004123.	3.5	150
71	Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2014, 106, djt376.	6.3	77
72	Ferritin Heavy Chain in Triple Negative Breast Cancer: A Favorable Prognostic Marker that Relates to a Cluster of Differentiation 8 Positive (CD8+) Effector T-cell Response. Molecular and Cellular Proteomics, 2014, 13, 1814-1827.	3.8	44

#	Article	IF	Citations
73	Serum FGF21 levels in adult m.3243A>G carriers. Neurology, 2014, 83, 125-133.	1.1	33
74	Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression. Molecular Pharmaceutics, 2014, 11, 4249-4257.	4.6	8
75	Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media and Molecular Imaging, 2014, 9, 237-245.	0.8	24
76	The psychophysiological stress response in psoriasis and rheumatoid arthritis. British Journal of Dermatology, 2014, 170, 824-831.	1.5	26
77	Gonadal status and outcome of bariatric surgery in obese men. Clinical Endocrinology, 2014, 81, 378-386.	2.4	23
78	Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. European Journal of Endocrinology, 2014, 170, 349-357.	3.7	25
79	Longitudinal trends in thyroid function in relation to iodine intake: ongoing changes of thyroid function despite adequate current iodine status. European Journal of Endocrinology, 2014, 170, 49-54.	3.7	21
80	Quantification of Patient-Specific Assay Interference in Different Formats of Enzyme-Linked Immunoassays for Therapeutic Monoclonal Antibodies. Therapeutic Drug Monitoring, 2014, 36, 765-770.	2.0	8
81	Harmonization of growth hormone measurement results: The empirical approach. Clinica Chimica Acta, 2014, 432, 72-76.	1.1	18
82	Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7379-7384.	7.1	185
83	Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nature Communications, 2014, 5, 4926.	12.8	192
84	Does stress affect the joints? Daily stressors, stress vulnerability, immune and HPA axis activity, and short-term disease and symptom fluctuations in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1683-1688.	0.9	49
85	Evaluation of the ability of adjuvant tamoxifenâ€benefit gene signatures to predict outcome of hormoneâ€naive estrogen receptorâ€positive breast cancer patients treated with tamoxifen in the advanced setting. Molecular Oncology, 2014, 8, 1679-1689.	4.6	18
86	Correlation Between In Vivo ¹⁸ F-FDG PET and Immunohistochemical Markers of Glucose Uptake and Metabolism in Pheochromocytoma and Paraganglioma. Journal of Nuclear Medicine, 2014, 55, 1253-1259.	5.0	67
87	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science, 2014, 345, 1251343.	12.6	348
88	The unfolded protein response as a target for cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 277-284.	7.4	60
89	LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy. Endocrine-Related Cancer, 2014, 21, 101-112.	3.1	82
90	Engineered Human Lipocalin as an Antibody Mimetic: Application to Analysis of the Small Peptide Hormone Hepcidin. Clinical Chemistry, 2014, 60, 897-899.	3.2	8

#	Article	IF	Citations
91	Associations between thyroid function and mortality: the influence of age. European Journal of Endocrinology, 2014, 171, 183-191.	3.7	25
92	A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. Lancet Oncology, The, 2014, 15, e184-e193.	10.7	30
93	Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids. International Journal of Oncology, 2014, 44, 1394-1400.	3.3	9
94	Pacemaker Current Inhibition in Experimental Human Cardiac Sympathetic Activation: A Double-Blind, Randomized, Crossover Study. Clinical Pharmacology and Therapeutics, 2014, 95, 601-607.	4.7	6
95	Utility of LC-MS/MS based adrenal venous steroid profiling: Should cortisol remain the gold standard for selectivity and comparisons to aldosterone?. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	1
96	Seasonal variation of plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	0
97	Abstract 1611: 4-protein signature predicts outcome to tamoxifen treatment in estrogen receptor positive recurrent breast cancer. , 2014, , .		0
98	Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response. Breast Cancer Research, 2013, 15, R2.	5.0	194
99	αB-crystallin stimulates VEGF secretion and tumor cell migration and correlates with enhanced distant metastasis in head and neck squamous cell carcinoma. BMC Cancer, 2013, 13, 128.	2.6	30
100	Signatures of mutational processes in human cancer. Nature, 2013, 500, 415-421.	27.8	8,060
101	Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. European Radiology, 2013, 23, 748-756.	4.5	65
102	Generation of multicellular tumor spheroids of breast cancer cells: How to go three-dimensional. Analytical Biochemistry, 2013, 437, 17-19.	2.4	57
103	The PERK/ATF4/LAMP3-arm of the unfolded protein response affects radioresistance by interfering with the DNA damage response. Radiotherapy and Oncology, 2013, 108, 415-421.	0.6	83
104	Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Annals of Clinical Biochemistry, 2013, 50, 62-69.	1.6	98
105	Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. European Journal of Cancer, 2013, 49, 860-867.	2.8	28
106	Maternal soluble fms-like tyrosine kinase-1, placental growth factor, plasminogen activator inhibitor-2, and folate concentrations and early fetal size: the Generation R study. American Journal of Obstetrics and Gynecology, 2013, 209, 121.e1-121.e11.	1.3	16
107	Impaired effect of relaxin on vasoconstrictor reactivity in spontaneous hypertensive rats. Peptides, 2013, 49, 41-48.	2.4	16
108	Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach. Investigational New Drugs, 2013, 31, 881-890.	2.6	7

#	Article	IF	CITATIONS
109	Ten-year analysis of the prospective multicentre Chemo-NO trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. European Journal of Cancer, 2013, 49, 1825-1835.	2.8	138
110	Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Research and Treatment, 2013, 139, 39-49.	2.5	49
111	Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP). Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1715-1722.	3.8	46
112	Single versus duplicate blood samples in ACTH stimulated adrenal vein sampling. Clinica Chimica Acta, 2013, 423, 15-17.	1.1	4
113	Subclinical Hypothyroidism after Vascular Complicated Pregnancy. Hypertension in Pregnancy, 2013, 32, 1-10.	1.1	4
114	A Meta-Analysis of Thyroid-Related Traits Reveals Novel Loci and Gender-Specific Differences in the Regulation of Thyroid Function. PLoS Genetics, 2013, 9, e1003266.	3.5	194
115	Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans. Hypertension, 2013, 61, 1060-1065.	2.7	50
116	Response to Catheter-Based Renal Nerve Ablation and Centrally Generated Sympathetic Activity in Difficult-to-Control Hypertensive Patients: Prospective Case Series. Hypertension, 2013, 61, e18.	2.7	0
117	Response to Blood Pressure and Sympathetic Nervous System Response to Renal Denervation. Hypertension, 2013, 61, e14.	2.7	1
118	Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2013, 19, 3787-3795.	7.0	53
119	Endocrine Disruptors Differentially Target ATP-Binding Cassette Transporters in the Blood-Testis Barrier and Affect Leydig Cell Testosterone Secretion In Vitro. Toxicological Sciences, 2013, 136, 382-391.	3.1	96
120	Plasma Metanephrine for Assessing the Selectivity of Adrenal Venous Sampling. Hypertension, 2013, 62, 1152-1157.	2.7	65
121	Associations of common variants in <i>HFE</i> and <i>TMPRSS6</i> with iron parameters are independent of serum hepcidin in a general population: a replication study. Journal of Medical Genetics, 2013, 50, 593-598.	3.2	34
122	Co-occurrence of Cardiovascular and Prothrombotic Risk Factors in Women With a History of Preeclampsia. Obstetrics and Gynecology, 2013, 121, 97-105.	2.4	39
123	Linear Regression of Postevacuation Serum Human Chorionic Gonadotropin Concentrations Predicts Postmolar Gestational Trophoblastic Neoplasia. International Journal of Gynecological Cancer, 2013, 23, 1151-1157.	2.5	17
124	Hypoxia Regulation of Phosphokinases and the Prognostic Value of pAKT in Breast Cancer. International Journal of Biological Markers, 2013, 28, 151-160.	1.8	11
125	αB-Crystallin Expression is Correlated with Phospho-ERK1/2 Expression in Human Breast Cancer. International Journal of Biological Markers, 2013, 28, 365-370.	1.8	5
126	Downregulation of Serine Protease HTRA1 Is Associated with Poor Survival in Breast Cancer. PLoS ONE, 2013, 8, e60359.	2.5	28

#	Article	IF	Citations
127	A functional microsatellite of the <i>macrophage migration inhibitory factor</i> gene associated with meningococcal disease. FASEB Journal, 2012, 26, 907-916.	0.5	50
128	Centralised registration of gestational trophoblastic disease and trends in incidence. Acta $Oncol\tilde{A}^3$ gica, 2012, 51, 415-416.	1.8	1
129	Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D,) Tj ETQq1 1 0.784314 rg	gB T. ‡Overl	ock 10 Tf 50
130	Impaired vascular responses to relaxin in diet-induced overweight female rats. Journal of Applied Physiology, 2012, 112, 962-969.	2.5	19
131	Is There a Relationship Between Fatigue Perception and the Serum Levels of Thyrotropin and Free Thyroxine in Euthyroid Subjects?. Thyroid, 2012, 22, 1236-1243.	4.5	30
132	Independent and functional validation of a multi-tumour-type proliferation signature. British Journal of Cancer, 2012, 107, 508-515.	6.4	17
133	Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biological Chemistry, 2012, 393, 391-401.	2.5	36
134	Fatal cases of gestational trophoblastic neoplasia over four decades in the Netherlands: a retrospective cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 1465-1472.	2.3	25
135	Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell and Tissue Research, 2012, 349, 551-563.	2.9	47
136	Expression of the BRCA1 complex member BRE predicts disease free survival in breast cancer. Breast Cancer Research and Treatment, 2012, 135, 125-133.	2.5	14
137	Catheter-Based Renal Nerve Ablation and Centrally Generated Sympathetic Activity in Difficult-to-Control Hypertensive Patients. Hypertension, 2012, 60, 1485-1490.	2.7	164
138	TRPM7 Is Required for Breast Tumor Cell Metastasis. Cancer Research, 2012, 72, 4250-4261.	0.9	186
139	Angiogenic and Fibrinolytic Factors in Blood During the First Half of Pregnancy and Adverse Pregnancy Outcomes. Obstetrics and Gynecology, 2012, 119, 1190-1200.	2.4	56
140	Association between thyroid function, thyroid autoimmunity, and state and trait factors of depression. Acta Psychiatrica Scandinavica, 2012, 126, 377-384.	4.5	57
141	Menopausal status and adjuvant hormonal therapy for breast cancer patients: A practical guideline. Critical Reviews in Oncology/Hematology, 2012, 84, 252-260.	4.4	36
142	Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection. Cytokine, 2012, 60, 338-340.	3.2	21
143	Regulation of TRIB3 mRNA and Protein in Breast Cancer. PLoS ONE, 2012, 7, e49439.	2.5	28
144	Aldo-keto Reductase Family 1 Member C3 (AKR1C3) Is a Biomarker and Therapeutic Target for Castration-Resistant Prostate Cancer. Molecular Medicine, 2012, 18, 1449-1455.	4.4	70

#	Article	IF	Citations
145	Bilateral thoracoscopic splanchnicectomy for pain in patients with chronic pancreatitis impairs adrenomedullary but not noradrenergic sympathetic function. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 2183-2188.	2.4	13
146	Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecologic Oncology, 2012, 125, 576-579.	1.4	79
147	Abstract P1-13-13: First planned efficacy analysis of the NNBC 3-Europe trial: Addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients, 2012,,.		1
148	Seasonal Variation in Vitamin D3 Levels Is Paralleled by Changes in the Peripheral Blood Human T Cell Compartment. PLoS ONE, 2012, 7, e29250.	2.5	62
149	Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood, 2011, 117, e218-e225.	1.4	246
150	Dopamine susceptibility of APO-SUS rats is not per se coupled to HPA-axis activity. Physiology and Behavior, 2011, 102, 121-125.	2.1	4
151	The <i>CYP2C19*2</i> genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics, 2011, 12, 1137-1146.	1.3	44
152	Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. Breast Cancer Research, 2011, 13, R82.	5.0	74
153	TRIB3 protein denotes a good prognosis in breast cancer patients and is associated with hypoxia sensitivity. Radiotherapy and Oncology, 2011, 101, 198-202.	0.6	37
154	Constitutive expression of \hat{I}^3 -H2AX has prognostic relevance in triple negative breast cancer. Radiotherapy and Oncology, 2011, 101, 39-45.	0.6	74
155	Adult Patients with Congenital Adrenal Hyperplasia Have Elevated Blood Pressure but Otherwise a Normal Cardiovascular Risk Profile. PLoS ONE, 2011, 6, e24204.	2.5	30
156	Regulation of cytokine responses by seasonality of vitamin D status in healthy individuals. Clinical and Experimental Immunology, 2011, 164, 72-79.	2.6	153
157	Increase in the incidence of gestational trophoblastic disease in The Netherlands. Gynecologic Oncology, 2011, 121, 334-338.	1.4	58
158	Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 \tilde{A} — FEC versus 3 \tilde{A} — FEC/3 \tilde{A} — Docetaxel. BMC Cancer, 2011, 11, 140.	2.6	40
159	Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: Comparison of prednisolone with budesonide. International Journal of Pharmaceutics, 2011, 416, 493-498.	5.2	27
160	Contribution of different local vascular responses to mid-gestational vasodilation. American Journal of Obstetrics and Gynecology, 2011, 205, 155.e12-155.e17.	1.3	4
161	FSH isoform pattern in classic galactosemia. Journal of Inherited Metabolic Disease, 2011, 34, 387-390.	3.6	22
162	Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer. Cancer, 2011, 117, 3670-3681.	4.1	57

#	Article	IF	Citations
163	Underestimation of Effect of Thyroid Function Parameters on Morbidity and Mortality due to Intra-Individual Variation. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E2014-E2017.	3.6	14
164	Overexpression of the natural antisense hypoxia-inducible factor- $1\hat{A}$ transcript is associated with malignant pheochromocytoma/paraganglioma. Endocrine-Related Cancer, 2011, 18, 323-331.	3.1	39
165	Spuriously High Free Thyroxine Values in Familial Dysalbuminemic Hyperthyroxinemia. Clinical Chemistry, 2011, 57, 524-525.	3.2	25
166	A study of longer-time stability of plasma free metanephrines. Annals of Clinical Biochemistry, 2011, 48, 270-271.	1.6	7
167	Aging attenuates the vasodilator response to relaxin. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H1609-H1615.	3.2	28
168	Liver Afferents Contribute to Water Drinking-Induced Sympathetic Activation in Human Subjects: A Clinical Trial. PLoS ONE, 2011, 6, e25898.	2.5	19
169	Psychophysiological Responses to Stress after Stress Management Training in Patients with Rheumatoid Arthritis. PLoS ONE, 2011, 6, e27432.	2.5	31
170	Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors. Journal of Cancer Research and Clinical Oncology, 2010, 136, 771-778.	2.5	26
171	Tamoxifen sensitivity and estrogen receptor mRNA levels. Breast Cancer Research and Treatment, 2010, 121, 793-794.	2.5	0
172	Placental urocortin-2 and -3: Endocrine or Paracrine Functioning During Healthy Pregnancy?. Placenta, 2010, 31, 475-481.	1.5	10
173	Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease. Gynecologic Oncology, 2010, 117, 47-52.	1.4	6
174	Usefulness of intraoperative parathyroid hormone measurements in patients with renal hyperparathyroidism. Head and Neck, 2010, 32, 1328-1335.	2.0	16
175	Metalloproteinases and their regulators in colorectal cancer. Journal of Surgical Oncology, 2010, 101, 259-269.	1.7	29
176	Mammaglobin RTâ€qPCR for breast cancer metastasis detection in sentinel lymph nodes. Cancer Science, 2010, 101, 2501-2501.	3.9	1
177	The balance between extracellular cathepsins and cystatin C is of importance for ovarian cancer. European Journal of Clinical Investigation, 2010, 40, 591-599.	3.4	28
178	Neurohumoral and Metabolic Response to Exercise in Water. Hormone and Metabolic Research, 2010, 42, 334-339.	1.5	20
179	Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers. Journal of Psychopharmacology, 2010, 24, 155-164.	4.0	28
180	Should anterior pituitary function be tested during follow-up of all patients presenting at the emergency department because of traumatic brain injury?. European Journal of Endocrinology, 2010, 162, 19-28.	3.7	47

#	Article	IF	CITATIONS
181	DC-SCRIPT: Nuclear Receptor Modulation and Prognostic Significance in Primary Breast Cancer. Journal of the National Cancer Institute, 2010, 102, 54-68.	6.3	22
182	Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology. Journal of Psychopharmacology, 2010, 24, 165-174.	4.0	23
183	Increased Sympathetic Activity in Chronic Pancreatitis Patients Is Associated With Hyperalgesia. Journal of Pain and Palliative Care Pharmacotherapy, 2010, 24, 362-366.	0.8	17
184	Carotid Baroreceptor Stimulation, Sympathetic Activity, Baroreflex Function, and Blood Pressure in Hypertensive Patients. Hypertension, 2010, 55, 619-626.	2.7	366
185	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 2784-2795.	1.6	2,667
186	Expression and Function of Macrophage Migration Inhibitory Factor (MIF) in Melioidosis. PLoS Neglected Tropical Diseases, 2010, 4, e605.	3.0	17
187	Immunochemical and Mass-Spectrometry–Based Serum Hepcidin Assays for Iron Metabolism Disorders. Clinical Chemistry, 2010, 56, 1570-1579.	3.2	190
188	Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer. Biological Chemistry, 2010, 391, 391-401.	2.5	35
189	Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Review of Molecular Diagnostics, 2010, 10, 1051-1067.	3.1	56
190	Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Review of Molecular Diagnostics, 2010, 10, 947-962.	3.1	43
191	Experimental stress in inflammatory rheumatic diseases: a review of psychophysiological stress responses. Arthritis Research and Therapy, 2010, 12, R89.	3.5	53
192	Is Overexpression of the Hypoxia-Inducible Factor-1alpha Natural Antisense Transcript a Marker of the Malignant Potential of Phaeochromocytoma?, 2010,, P3-619-P3-619.		0
193	Composite Reference Interval for Thyroid-Stimulating Hormone and Free Thyroxine, Comparison with Common Cutoff Values, and Reconsideration of Subclinical Thyroid Disease. Clinical Chemistry, 2009, 55, 2019-2025.	3.2	14
194	Genomic actions of estrogen receptor $\hat{l}\pm$: what are the targets and how are they regulated?. Endocrine-Related Cancer, 2009, 16, 1073-1089.	3.1	128
195	Secondary Ovarian Malignancies. International Journal of Gynecological Cancer, 2009, 19, 1160-1165.	2.5	104
196	Inactivating <i>PAPSS2 </i> Mutations in a Patient with Premature Pubarche. New England Journal of Medicine, 2009, 360, 2310-2318.	27.0	139
197	Pioglitazone Treatment Enlarges Subcutaneous Adipocytes in Insulin-Resistant Patients. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4453-4457.	3.6	34
198	The Relationship between Central Adrenal Insufficiency and Sleep-Related Breathing Disorders in Children with Prader-Willi Syndrome. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2387-2393.	3.6	29

#	Article	IF	CITATIONS
199	Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 846-852.	3.6	105
200	Placental Urocortins and CRF in Late Gestation. Placenta, 2009, 30, 483-490.	1.5	11
201	Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 1749-1758.	4.1	48
202	Serum vascular endothelial growth factor: a prognostic factor in cervical cancer. Journal of Cancer Research and Clinical Oncology, 2009, 135, 283-290.	2.5	26
203	The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Research and Treatment, 2009, 116, 303-309.	2.5	134
204	Highâ€sensitive radioimmunoassay for human serum hepcidin. British Journal of Haematology, 2009, 146, 317-325.	2.5	58
205	Effect of naproxen on the hypothalamic–pituitary– adrenal axis in healthy volunteers. British Journal of Clinical Pharmacology, 2009, 67, 22-28.	2.4	6
206	Cannabis Coadministration Potentiates the Effects of "Ecstasy―on Heart Rate and Temperature in Humans. Clinical Pharmacology and Therapeutics, 2009, 86, 160-166.	4.7	41
207	ChIP-Seq of ERÎ \pm and RNA polymerase II defines genes differentially responding to ligands. EMBO Journal, 2009, 28, 1418-1428.	7.8	377
208	External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. British Journal of Cancer, 2009, 100, 979-984.	6.4	15
209	Carbohydrate antigen 19â€9 is extremely elevated in polycystic liver disease. Liver International, 2009, 29, 1389-1395.	3.9	66
210	Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: An EU-FP6 supported study of members of the EORTC – PathoBiology Group. European Journal of Cancer, 2009, 45, 74-81.	2.8	2
211	Methylated genes as new cancer biomarkers. European Journal of Cancer, 2009, 45, 335-346.	2.8	92
212	Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer. European Journal of Cancer, 2009, 45, 2444-2446.	2.8	3
213	Occurrence of postmenopausal-like acidic follicle-stimulating hormone (FSH) isoforms precedes the rise of FSH before menopause. Fertility and Sterility, 2009, 92, 613-619.	1.0	5
214	Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvascular Research, 2009, 77, 96-103.	2.5	84
215	Vascular Endothelial Growth Factor in Systemic Capillary Leak Syndrome. American Journal of Medicine, 2009, 122, e5-e7.	1.5	57
216	Testicular adrenal rest tumours in congenital adrenal hyperplasia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 209-220.	4.7	152

#	Article	IF	Citations
217	Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Social Neuroscience, 2009, 4, 359-366.	1.3	202
218	Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer. Oncology Reports, 2009, 23, .	2.6	3
219	Rho GDP dissociation inhibitor \hat{l}_{\pm} expression correlates with the outcome of CMF treatment in invasive ductal breast cancer. International Journal of Oncology, 2009, 36, .	3.3	2
220	Earlier Diagnosis and Serum Human Chorionic Gonadotropin Regression in Complete Hydatidiform Moles. Obstetrics and Gynecology, 2009, 113, 326-331.	2.4	22
221	Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. International Journal of Cancer, 2008, 123, 1848-1853.	5.1	44
222	Protein kinase Cl´ expression in breast cancer as measured by real-time PCR, western blotting and ELISA. British Journal of Cancer, 2008, 99, 1644-1650.	6.4	35
223	Early identification of persistent trophoblastic disease with serum hCG concentration ratios. International Journal of Gynecological Cancer, 2008, 18, 318-323.	2.5	13
224	Maternal behavior predicts infant cortisol recovery from a mild everyday stressor. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2008, 49, 97-103.	5.2	171
225	The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin Dâ€deficient HIVâ€1â€infected patients. HIV Medicine, 2008, 9, 771-779.	2.2	31
226	Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. BJU International, 2008, 102, 177-182.	2.5	19
227	A decrease of plasma macrophage migration inhibitory factor concentration is associated with lower numbers of circulating lymphocytes in experimental Plasmodium falciparum malaria. Parasite Immunology, 2008, 30, 133-138.	1.5	23
228	Transient human anti-mouse antibodies (HAMA) interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody. Gynecologic Oncology, 2008, 109, 199-202.	1.4	8
229	Molecular aspects of tumour hypoxia. Molecular Oncology, 2008, 2, 41-53.	4.6	126
230	Cox-2 is a target gene of Rho GDP dissociation inhibitor beta in breast cancer cells. European Journal of Cancer, Supplement, 2008, 6, 82.	2.2	0
231	Matrix metalloproteinase-8 is a regulator of the clinical aggressiveness of mammary tumours. Breast Cancer Research, 2008, 10 , .	5.0	0
232	Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause severe testicular damage. Fertility and Sterility, 2008, 89, 597-601.	1.0	119
233	Review of the role of the plasminogen activator system and vascular endothelial growth factor in subfertility. Fertility and Sterility, 2008, 90, 2340-2350.	1.0	65
234	Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. European Journal of Cancer, 2008, 44, 1835-1840.	2.8	59

#	Article	IF	CITATIONS
235	Assay bias may invalidate decision limits and affect comparability of serum thyroglobulin assay methods: An approach to reduce interpretation differences. Clinica Chimica Acta, 2008, 394, 104-109.	1.1	14
236	P.1.c.040 MDMA induces oxytocin release in humans. European Neuropsychopharmacology, 2008, 18, S242.	0.7	0
237	PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. Radiotherapy and Oncology, 2008, 86, 361-368.	0.6	20
238	890 CA19-9 IS A NOVEL BIOMARKER FOR POLYCYSTIC LIVER DISEASE. Journal of Hepatology, 2008, 48, S334.	3.7	0
239	Vitamin D Deficiency among HIV Type 1-Infected Individuals in the Netherlands: Effects of Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2008, 24, 1375-1382.	1.1	158
240	Banking of Biological Fluids for Studies of Disease-associated Protein Biomarkers. Molecular and Cellular Proteomics, 2008, 7, 2061-2066.	3.8	95
241	Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocrine-Related Cancer, 2008, 15, 1127-1133.	3.1	44
242	Distinct Functions of Natural ADAM-15 Cytoplasmic Domain Variants in Human Mammary Carcinoma. Molecular Cancer Research, 2008, 6, 383-394.	3.4	60
243	Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: Comparison to antigen quantification by ELISA. International Journal of Molecular Medicine, 2008, , .	4.0	11
244	Prospective Biomarker Trials Chemo NO and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer. Breast Care, 2008, 3, 3-3.	1.4	7
245	Impaired Sertoli Cell Function in Males Diagnosed with Noonan Syndrome. Journal of Pediatric Endocrinology and Metabolism, 2008, 21, 1079-84.	0.9	39
246	Matrix Metalloproteinase-8 Functions as a Metastasis Suppressor through Modulation of Tumor Cell Adhesion and Invasion. Cancer Research, 2008, 68, 2755-2763.	0.9	172
247	High Prevalence of Central Adrenal Insufficiency in Patients with Prader-Willi Syndrome. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1649-1654.	3.6	126
248	Atrial Natriuretic Peptide Induces Postprandial Lipid Oxidation in Humans. Diabetes, 2008, 57, 3199-3204.	0.6	125
249	Biomarkers for Breast Cancer: Towards the Proposition of Clinically Relevant Tools., 2008,, 15-32.		0
250	Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. International Journal of Molecular Medicine, 2008, 21, 251-9.	4.0	27
251	Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer. British Journal of Cancer, 2007, 96, 1309-1309.	6.4	7
252	Testicular Tumors in Patients with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency Show Functional Features of Adrenocortical Tissue. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3674-3680.	3.6	109

#	Article	IF	Citations
253	Stability of Urinary Fractionated Metanephrines and Catecholamines during Collection, Shipment, and Storage of Samples. Clinical Chemistry, 2007, 53, 268-272.	3.2	64
254	Re: p27Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant Chemotherapy. Journal of the National Cancer Institute, 2007, 99, 738-738.	6.3	5
255	Association between High Levels of Blood Macrophage Migration Inhibitory Factor, Inappropriate Adrenal Response, and Early Death in Patients with Severe Sepsis. Clinical Infectious Diseases, 2007, 44, 1321-1328.	5.8	98
256	Is Supine Rest Necessary before Blood Sampling for Plasma Metanephrines?. Clinical Chemistry, 2007, 53, 352-354.	3.2	110
257	Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. European Journal of Endocrinology, 2007, 157, 339-344.	3.7	132
258	<i>Cyclooxygenase-2</i> Is a Target Gene of Rho GDP Dissociation Inhibitor \hat{I}^2 in Breast Cancer Cells. Cancer Research, 2007, 67, 10694-10702.	0.9	29
259	MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) IN MENINGOCOCCAL SEPTIC SHOCK AND EXPERIMENTAL HUMAN ENDOTOXEMIA. Shock, 2007, 27, 482-487.	2.1	29
260	Exhaustion is Associated With Low Macrophage Migration Inhibitory Factor Expression in Patients With Coronary Artery Disease. Psychosomatic Medicine, 2007, 69, 68-73.	2.0	9
261	European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers. European Journal of Cancer, 2007, 43, 835-844.	2.8	32
262	Complex congenital malformations and the impact of the plasminogen activator system and \hat{l}^2 -hCG in amniotic fluid. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 135, 47-52.	1.1	5
263	Antim $\tilde{A}\frac{1}{4}$ llerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertility and Sterility, 2007, 87, 223-226.	1.0	170
264	Possible role of the plasminogen activation system in human subfertility. Fertility and Sterility, 2007, 87, 619-626.	1.0	25
265	Repeated successful induction of fertility after replacing hydrocortisone with dexamethasone in a patient with congenital adrenal hyperplasia and testicular adrenal rest tumors. Fertility and Sterility, 2007, 88, 705.e5-705.e8.	1.0	73
266	Antibody GD3G7 Selected against Embryonic Glycosaminoglycans Defines Chondroitin Sulfate-E Domains Highly Up-Regulated in Ovarian Cancer and Involved in Vascular Endothelial Growth Factor Binding. American Journal of Pathology, 2007, 171, 1324-1333.	3.8	105
267	Early identification of treatment resistance in GTN. Lancet Oncology, The, 2007, 8, 866-867.	10.7	1
268	Biomarkers for therapeutic efficacy. European Journal of Cancer, Supplement, 2007, 5, 129-142.	2,2	4
269	Testicular Adrenal Rest Tumors in Adult Males with Congenital Adrenal Hyperplasia: Evaluation of Pituitary-Gonadal Function before and after Successful Testis-Sparing Surgery in Eight Patients. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 612-615.	3.6	122
270	Identifying estrogen receptor target genes. Molecular Oncology, 2007, 1, 138-143.	4.6	61

#	Article	IF	Citations
271	Identification and characterization of multiple species of tenascin-X in human serum. FEBS Journal, 2007, 274, 1280-1289.	4.7	14
272	Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines. BMC Cancer, 2007, 7, 143.	2.6	17
273	Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases. Clinical Immunology, 2007, 123, 60-65.	3.2	13
274	Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands. Gynecologic Oncology, 2007, 106, 142-146.	1.4	31
275	Is survivin expression nevertheless related to disease outcome in breast cancer?. Breast Cancer Research and Treatment, 2007, 103, 109-109.	2.5	3
276	237 Investigation of plasminogen activator inhibitor-1 (PAI-1) as an endogenous hypoxia marker in human head and neck carcinoma cell lines. Radiotherapy and Oncology, 2006, 78, S84.	0.6	0
277	Follicle-stimulating hormone isoforms are not useful as pretreatment predictors of outcome in in vitro fertilization: a pilot study. Fertility and Sterility, 2006, 85, 1519-1522.	1.0	4
278	Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Letters, 2006, 237, 289-297.	7.2	55
279	MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis. Cytokine, 2006, 36, 51-56.	3.2	31
280	Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 128, 22-28.	1.1	42
281	Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. Proteomics, 2006, 6, 1427-1436.	2.2	39
282	Haematopoietic stem cells and endothelial progenitor cells in healthy men: effect of aging and training. Aging Cell, 2006, 5, 495-503.	6.7	132
283	Forearm vasoconstrictor response in uncomplicated type 1 diabetes mellitus. European Journal of Clinical Investigation, 2006, 36, 674-681.	3.4	5
284	Fertility in Patients with Congenital Adrenal Hyperplasia. Journal of Pediatric Endocrinology and Metabolism, 2006, 19, 677-85.	0.9	45
285	High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. Breast Cancer Research and Treatment, 2006, 98, 223-230.	2.5	32
286	ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. International Journal of Cancer, 2006, 118, 1241-1247.	5.1	82
287	Molecular profiling of platinum resistant ovarian cancer. International Journal of Cancer, 2006, 118, 1963-1971.	5.1	139
288	Sympathetic nervous system function in HIV-associated adipose redistribution syndrome. Aids, 2006, 20, 773-775.	2.2	17

#	Article	IF	Citations
289	Effect of Reoxygenation on the Hypoxia-Induced Up-Regulation of Serine Protease Inhibitor PAI-1 in Head and Neck Cancer Cells. Oncology, 2006, 71, 282-291.	1.9	14
290	Sperm integrity pre- and post-chemotherapy in men with testicular germ cell cancer. Human Reproduction, 2006, 21, 1781-1786.	0.9	96
291	Absence of Exercise-Induced Leptin Suppression Associated with Insufficient Epinephrine Reserve in Patients with Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, 105-110.	1.2	26
292	Virilization due to ovarian androgen hypersecretion in a patient with ectopic adrenocorticotrophic hormone secretion caused by a carcinoid tumour: Case Report. Human Reproduction, 2006, 21, 2601-2605.	0.9	5
293	CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology, 2006, 67, 114-119.	1.1	31
294	Early Identification of Resistance to First-Line Single-Agent Methotrexate in Patients With Persistent Trophoblastic Disease. Journal of Clinical Oncology, 2006, 24, 52-58.	1.6	36
295	Multicenter Validation of a Gene Expression–Based Prognostic Signature in Lymph Node–Negative Primary Breast Cancer. Journal of Clinical Oncology, 2006, 24, 1665-1671.	1.6	328
296	Parathyroid Hormone-related Protein Regulates Tumor-relevant Genes in Breast Cancer Cells*. Journal of Biological Chemistry, 2006, 281, 14563-14572.	3.4	36
297	Transport within the Interstitial Space, Rather Than Membrane Permeability, Determines Norepinephrine Recovery in Microdialysis. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 840-846.	2.5	6
298	Quantitative Reverse Transcription-PCR Assay for Detection of mRNA Encoding Full-Length Human Tissue Kallikrein 7: Prognostic Relevance of KLK7 mRNA Expression in Breast Cancer 3. Clinical Chemistry, 2006, 52, 1070-1079.	3.2	20
299	Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing's disease. European Journal of Endocrinology, 2006, 154, 675-684.	3.7	82
300	Do the Survivin (BIRC5) Splice Variants Modulate or Add to the Prognostic Value of Total Survivin in Breast Cancer?. Clinical Chemistry, 2006, 52, 1693-1700.	3.2	51
301	Thyroid Function and Prevalence of Anti-Thyroperoxidase Antibodies in a Population with Borderline Sufficient Iodine Intake: Influences of Age and Sex. Clinical Chemistry, 2006, 52, 104-111.	3.2	199
302	Plasma metanephrines in renal failure. Kidney International, 2005, 67, 668-677.	5.2	73
303	Second curettage in persistent trophoblastic disease (PTD): the need for univocal definition of PTD. Gynecologic Oncology, 2005, 99, 250-251.	1.4	7
304	The curative effect of a second curettage in persistent trophoblastic disease: A retrospective cohort survey. Gynecologic Oncology, 2005, 99, 6-13.	1.4	63
305	Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis and Rheumatism, 2005, 52, 3020-3029.	6.7	203
306	Adrenergic receptor stimulation attenuates insulin-stimulated glucose uptake in 3T3-L1 adipocytes by inhibiting GLUT4 translocation. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E627-E633.	3 . 5	43

#	Article	IF	CITATIONS
307	Concerns about Mammaglobin Assays. Clinical Chemistry, 2005, 51, 474-475.	3.2	O
308	Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG \hat{l}_{\pm} - and \hat{l}^2 -subunits, and their ratios. European Journal of Endocrinology, 2005, 153, 565-575.	3.7	26
309	A simple method for estimating equilibrium constants for serum testosterone binding resulting in an optimal free testosterone index for use in elderly men. Clinical Chemistry and Laboratory Medicine, 2005, 43, 613-6.	2.3	13
310	Stress and outcome success in IVF: the role of self-reports and endocrine variables. Human Reproduction, 2005, 20, 991-996.	0.9	112
311	Mammaglobin as Molecular Marker of Breast Cancer (Micro)Metastases. Clinical Cancer Research, 2005, 11, 7043-7044.	7.0	5
312	Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. European Journal of Cancer, 2005, 41, 2760-2768.	2.8	44
313	The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) independently predicts response to first-line endocrine therapy in advanced breast cancer. Thrombosis and Haemostasis, 2004, 91, 514-521.	3.4	12
314	High Levels of Urinary Vascular Endothelial Growth Factor in Women with Severe Preeclampsia. International Journal of Biological Markers, 2004, 19, 72-75.	1.8	8
315	Role of Hexosamines in Insulin Resistance and Nutrient Sensing in Human Adipose and Muscle Tissue. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5132-5137.	3.6	10
316	Plasma Metanephrine Levels Are Decreased in Type 1 Diabetic Patients with a Severely Impaired Epinephrine Response to Hypoglycemia, Indicating Reduced Adrenomedullary Stores of Epinephrine. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2057-2061.	3.6	11
317	Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing) Tj ETQq1 1 0.78431 arthritis. Annals of the Rheumatic Diseases, 2004, 64, 368-374.	.4 rgBT /C 0.9	
318	Development of an ELISA for Measurement of BCAR1 Protein in Human Breast Cancer Tissue. Clinical Chemistry, 2004, 50, 1356-1363.	3.2	12
319	High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcÂR triggering. Annals of the Rheumatic Diseases, 2004, 63, 696-702.	0.9	44
320	Predictive Impact of Urokinase-Type Plasminogen Activator. Cancer Research, 2004, 64, 659-664.	0.9	41
321	The Prognostic Value of BCAR1 in Patients with Primary Breast Cancer. Clinical Cancer Research, 2004, 10, 6194-6202.	7.0	51
322	Mammaglobin Is Associated With Low-Grade, Steroid Receptor-Positive Breast Tumors From Postmenopausal Patients, and Has Independent Prognostic Value for Relapse-Free Survival Time. Journal of Clinical Oncology, 2004, 22, 691-698.	1.6	75
323	Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: Tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. International Journal of Oncology. 2004. 25. 1397.	3.3	5
324	Survivin Is an Independent Prognostic Marker for Risk Stratification of Breast Cancer Patients. Clinical Chemistry, 2004, 50, 1986-1993.	3.2	121

#	Article	IF	Citations
325	Pitfall in HPLC Assay for Urinary Metanephrines: An Unusual Type of Interference Caused by Methenamine Intake. Clinical Chemistry, 2004, 50, 1097-1099.	3.2	13
326	Application of a Newly Developed ELISA for BCAR1 Protein for Prediction of Clinical Benefit of Tamoxifen Therapy in Patients with Advanced Breast Cancer. Clinical Chemistry, 2004, 50, 1445-1447.	3.2	9
327	Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity. Annals of the Rheumatic Diseases, 2004, 64, 433-437.	0.9	13
328	Hexosamines Are Unlikely to Function as a Nutrient-Sensor in 3T3-L1 Adipocytes: A Comparison of UDP-Hexosamine Levels after Increased Glucose Flux and Glucosamine Treatment. Endocrine, 2004, 23, 17-24.	2.2	14
329	Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS. Pediatric Nephrology, 2004, 19, 754-760.	1.7	19
330	Biomolecular features of clinical relevance in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, S3-S14.	6.4	13
331	Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. Journal of Pathology, 2004, 202, 395-402.	4.5	44
332	Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node–negative breast carcinoma. Cancer, 2004, 101, 486-494.	4.1	35
333	Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation. Diabetes/Metabolism Research and Reviews, 2004, 20, 466-471.	4.0	16
334	Metabolic profile of the hippocampus of Zucker Diabetic Fatty rats assessed byin vivo1H magnetic resonance spectroscopy. NMR in Biomedicine, 2004, 17, 405-410.	2.8	49
335	Percutaneous epididymal sperm aspiration: a diagnostic tool for the prediction of complete spermatogenesis. Reproductive BioMedicine Online, 2004, 8, 657-663.	2.4	10
336	Regulation of GLUT1-mediated glucose uptake by PKCλ–PKCβII interactions in 3T3-L1 adipocytes. Biochemical Journal, 2004, 384, 349-355.	3.7	16
337	High levels of urinary vascular endothelial growth factor in women with severe preeclampsia. International Journal of Biological Markers, 2004, 19, 72-75.	1.8	4
338	Exploring Levels of Hexosamine Biosynthesis Pathway Intermediates and Protein Kinase C Isoforms in Muscle and Fat Tissue of Zucker Diabetic Fatty Rats. Endocrine, 2003, 20, 247-252.	2.2	10
339	E1AF Expression Levels are not Associated with Prognosis in Human Breast Cancer. Breast Cancer Research and Treatment, 2003, 79, 129-131.	2.5	7
340	The Prognostic Value of the Mitotic Activity Index in Patients with Primary Breast Cancer Who were not Treated with Adjuvant Systemic Therapy. Breast Cancer Research and Treatment, 2003, 77, 77-84.	2.5	19
341	Ethnic Variations in Uterine Leiomyoma Biology Are Not Caused By Differences in Myometrial Estrogen Receptor Alpha Levels. Journal of the Society for Gynecologic Investigation, 2003, 10, 105-109.	1.7	6
342	Matrix metalloproteinase inhibitor reversionâ€inducing cysteineâ€ich protein with Kazal motifs. Cancer, 2003, 97, 2710-2715.	4.1	92

#	Article	IF	CITATIONS
343	Increased expression of $Fc\hat{l}^3$ receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor \hat{l}_\pm and matrix metalloproteinase. Arthritis and Rheumatism, 2003, 48, 1002-1014.	6.7	70
344	Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene, 2003, 22, 4898-4904.	5.9	79
345	Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue. Prostate Cancer and Prostatic Diseases, 2003, 6, 131-137.	3.9	20
346	Monitoring of menstrual cycles, ovulation, and adrenal suppression by saliva sampling in female patients with 21-hydroxylase deficiency. Fertility and Sterility, 2003, 80, 1030-1036.	1.0	22
347	Inhibition of Protein Kinase $\hat{Cl^2}$ Illncreases Glucose Uptake in 3T3-L1 Adipocytes through Elevated Expression of Glucose Transporter 1 at the Plasma Membrane. Molecular Endocrinology, 2003, 17, 1230-1239.	3.7	16
348	Kinetics of myo-inositol loading in women of reproductive age. Annals of Clinical Biochemistry, 2003, 40, 79-85.	1.6	31
349	Tumor Markers. Molecular and Cellular Proteomics, 2003, 2, 378-387.	3.8	62
350	An improved procedure for testing for assay linearity. Annals of Clinical Biochemistry, 2003, 40, 75-78.	1.6	3
351	Molecular Beacon Reverse Transcription-PCR of Human Chorionic Gonadotropin- $\hat{1}^2$ -3, -5, and -8 mRNAs Has Prognostic Value in Breast Cancer. Clinical Chemistry, 2003, 49, 1074-1080.	3.2	24
352	Improved Cardiovascular Risk Profile and Renal Function in Renal Transplant Patients after Randomized Conversion from Cyclosporine to Tacrolimus. Journal of the American Society of Nephrology: JASN, 2003, 14, 1880-1888.	6.1	106
353	Quantitative detection of peripheral thyroglobulin mRNA has limited clinical value in the follow-up of thyroid cancer patients. Annals of Clinical Biochemistry, 2003, 40, 94-99.	1.6	33
354	Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. British Journal of Cancer, 2003, 89, 271-276.	6.4	102
355	Screening for Interference in Immunoassays. Clinical Chemistry, 2003, 49, 1708-1709.	3.2	14
356	Stability of Plasma Free Metanephrines during Collection and Storage as Assessed by an Optimized HPLC Method with Electrochemical Detection. Clinical Chemistry, 2003, 49, 1951-1953.	3.2	40
357	Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: An EORTC-NCI working group report. International Journal of Oncology, 2003, 23, 1715.	3.3	8
358	Antecedent Adrenaline Attenuates the Responsiveness to But Not the Release of Counterregulatory Hormones during Subsequent Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5462-5467.	3.6	13
359	Pretreatment with a Single, Low Dose of Recombinant Human Thyrotropin Allows Dose Reduction of Radioiodine Therapy in Patients with Nodular Goiter. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3121-3129.	3.6	109
360	Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function. European Journal of Heart Failure, 2003, 5, 47-53.	7.1	31

#	Article	IF	CITATIONS
361	Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels. Journal of the Society for Gynecologic Investigation, 2003, 10, 105-109.	1.7	16
362	Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thrombosis and Haemostasis, 2003, 90, 538-48.	3.4	39
363	Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report. International Journal of Oncology, 2003, 23, 1715-26.	3.3	5
364	Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients. Clinical Cancer Research, 2003, 9, 6363-70.	7.0	32
365	An Adolescent with Food-Dependent Cushing's Syndrome Secondary to Ectopic Expression of GIP Receptor in Unilateral Adrenal Adenoma. Journal of Pediatric Endocrinology and Metabolism, 2002, 15, 853-60.	0.9	13
366	uPA-Silica-Particles (SP-uPA): A Novel Analytical System to Investigate uPA-uPAR Interaction and to Test Synthetic uPAR Antagonists as Potential Cancer Therapeutics. Biological Chemistry, 2002, 383, 207-16.	2.5	5
367	Serial Plasma Concentrations of Atrial Natriuretic Peptide, Plasma Renin Activity, Aldosterone, and Antidiuretic Hormone in Neonates on Extracorporeal Membrane Oxygenation. ASAIO Journal, 2002, 48, 26-33.	1.6	17
368	Muscle Uridine Diphosphate-Hexosamines Do Not Decrease Despite Correction of Hyperglycemia-Induced Insulin Resistance in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5179-5184.	3.6	17
369	Expression of the Novel Epithelial Ca2+ Channel ECaC1 in Rat Pancreatic Islets. Journal of Histochemistry and Cytochemistry, 2002, 50, 789-798.	2.5	30
370	Analysis of expression of chorionic gonadotrophin transcripts in prostate cancer by quantitative Taqman and a modified molecular beacon RT-PCR. Journal of Endocrinology, 2002, 172, 489-495.	2.6	18
371	Acute intrarenal administration of cortisol has no effect on renal blood flow in hypertensive individuals. Journal of Hypertension, 2002, 20, 2275-2283.	0.5	9
372	Effect of glycyrrhetinic acid on $11\hat{l}^2$ -hydroxysteroid dehydrogenase activity in normotensive and hypertensive subjects. Clinical Science, 2002, 102, 203.	4.3	9
373	Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. American Journal of Obstetrics and Gynecology, 2002, 187, 1019-1025.	1.3	42
374	An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood. Journal of Immunological Methods, 2002, 268, 219-231.	1.4	36
375	Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer, 2002, 95, 641-655.	4.1	104
376	Stimulation of growth-hormone release with clonidine does not distinguish individual cases of idiopathic Parkinson's disease from those with Striatonigral Degeneration. Journal of Neurology, 2002, 249, 1206-1210.	3.6	15
377	Short-term cortisol infusion in the brachial artery, with and without inhibiting $11\hat{l}^2$ -hydroxysteroid dehydrogenase, does not alter forearm vascular resistance in normotensive and hypertensive subjects. European Journal of Clinical Investigation, 2002, 32, 874-881.	3.4	9
378	Developmental toxicity but no immunotoxicity in the rat after prenatal exposure to diethylstilbestrol. Toxicology, 2002, 174, 173-181.	4.2	18

#	Article	IF	Citations
379	Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene, 2002, 21, 8506-8509.	5.9	148
380	The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. British Journal of Cancer, 2002, 87, 772-778.	6.4	82
381	Fetal Growth and the Function of the Adrenal Cortex in Preterm Infants. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1194-1199.	3.6	15
382	Tumour VEGF levels in relation to efficacy of systematic therapy for specific sites of breast cancer metastases. European Journal of Cancer, 2002, 38, S112.	2.8	0
383	Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies. Obstetrics and Gynecology, 2001, 97, 404-408.	2.4	11
384	Serum Tumor Markers: Past, State of the Art, and Future. International Journal of Biological Markers, 2001, 16, 73-86.	1.8	32
385	Development of Quality Control Preparations for Immunocytochemical Assessment of Urokinase-type Plasminogen Activator. Applied Immunohistochemistry and Molecular Morphology, 2001, 9, 281-287.	1.2	0
386	Plasminogen Activator System in Serum and Amniotic Fluid of Euploid and Aneuploid Pregnancies. Obstetrics and Gynecology, 2001, 97, 404-408.	2.4	8
387	Evaluation of specific high-performance liquid-chromatographic determinations of urinary metanephrine and normetanephrine by comparison with isotope dilution mass spectrometry. Annals of Clinical Biochemistry, 2001, 38, 722-730.	1.6	32
388	Bone Mineral Density and Quantitative Ultrasound Parameters in Patients with Klinefelter's Syndrome after Long-Term Testosterone Substitution. Osteoporosis International, 2001, 12, 55-62.	3.1	80
389	Growth hormone (GH) secretion in children with Noonan syndrome: frequently abnormal without consequences for growth or response to GH treatment. Clinical Endocrinology, 2001, 54, 53-59.	2.4	50
390	Vascular endothelial growth factor in ovarian cyst fluid. Cancer, 2001, 91, 371-377.	4.1	29
391	Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. British Journal of Cancer, 2001, 85, 85-92.	6.4	40
392	Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1. Journal of the National Cancer Institute, 2001, 93, 913-920.	6.3	414
393	Relationship between free and total 1,25-dihydroxyvitamin D in conditions of modified binding. European Journal of Endocrinology, 2001, 144, 391-396.	3.7	53
394	Progressive histopathological changes in pancreatic islets of Zucker Diabetic Fatty rats. Experimental and Clinical Endocrinology and Diabetes, 2001, 109, 273-282.	1.2	36
395	High Prevalence of Testicular Adrenal Rest Tumors, Impaired Spermatogenesis, and Leydig Cell Failure in Adolescent and Adult Males with Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5721-5728.	3.6	73
396	Gender Differences in rhGH-Induced Changes in Body Composition in GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4161-4165.	3.6	14

#	Article	IF	CITATIONS
397	Calcitriol Controls the Epithelial Calcium Channel in Kidney. Journal of the American Society of Nephrology: JASN, 2001, 12, 1342-1349.	6.1	220
398	Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators., 2000, 86, 760-767.		49
399	Partial sequencing and tissue distribution of the canine isoforms of steroid 5?-Reductase type I and type II. Prostate, 2000, 44, 233-239.	2.3	9
400	Does Plasminogen Activator Inhibitor-1 (PAI-1) Control Trophoblast Invasion? A Study of Fetal and Maternal Tissue in Intrauterine, Tubal and Molar Pregnancies. Placenta, 2000, 21, 754-762.	1.5	46
401	EORTC Receptor and Biomarker Study Group Report: A Sandwich Enzyme-Linked Immunosorbent Assay for Vascular Endothelial Growth Factor in Blood and Tumor Tissue Extracts. International Journal of Biological Markers, 2000, 15, 184-191.	1.8	38
402	EORTC External Quality Assurance Program for ER and PgR Measurements: Trial 1998/1999. International Journal of Biological Markers, 2000, 15, 62-69.	1.8	16
403	Gender Difference in Insulin-Like Growth Factor I Response to Growth Hormone (GH) Treatment in GH-Deficient Adults: Role of Sex Hormone Replacement. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1121-1125.	3.6	30
404	Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice 1. Medical Mycology, 1999, 37, 419-426.	0.7	62
405	In Zucker Diabetic Fatty Rats Plasma Leptin Levels are Correlated with Plasma Insulin Levels rather than with Body Weight. Hormone and Metabolic Research, 1999, 31, 610-615.	1.5	17
406	The use of acupuncture in the treatment of erectile dysfunction. International Journal of Impotence Research, 1999, 11, 41-46.	1.8	41
407	Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. British Journal of Cancer, 1999, 79, 1190-1198.	6.4	38
408	Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. British Journal of Cancer, 1999, 79, 1534-1541.	6.4	38
409	ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA?PAI-1 and tPA?PAI-1)., 1999, 81, 598-606.		23
410	SELECTIVITY OF FINASTERIDE AS AN IN VIVO INHIBITOR OF 5 alpha-REDUCTASE ISOZYME ENZYMATIC ACTIVITY IN THE HUMAN PROSTATE. Journal of Urology, 1999, 161, 332-337.	0.4	73
411	DEPRESSION OF PLASMA LEVELS OF CYTOKINES AND EX-VIVO CYTOKINE PRODUCTION IN RELATION TO THE ACTIVITY OF THE PITUITARY–ADRENAL AXIS, IN PATIENTS UNDERGOING MAJOR VASCULAR SURGERY. Cytokine, 1999, 11, 382-388.	3.2	12
412	Immune Responses to Experimental Stress. Psychosomatic Medicine, 1999, 61, 513-524.	2.0	61
413	Influence of peritoneal loss of GHBP, IGF-I and IGFBP-3 on serum levels in children with ESRD. Nephrology Dialysis Transplantation, 1999, 14, 257-258.	0.7	3
414	Plasma Concentrations of Atrial Natriuretic Peptide (ANP), Plasma Renin Activity (PRA), Aldosterone (Aldo) and Arginine-Vasopressin (AVP) in Neonates on Extracorporeal Membrane Oxygenation (ECMO). Pediatric Research, 1999, 45, 224A-224A.	2.3	0

#	Article	IF	CITATIONS
415	External quality assessment of trans-European multicentre antigen determinations (enzyme-linked) Tj ETQq1 1 0. human breast cancer tissue extracts. British Journal of Cancer, 1998, 78, 1434-1441.	784314 rg 6.4	gBT /Overloc 118
416	Cardiovascular and endocrine responses to experimental stress: Effects of mental effort and controllability. Psychoneuroendocrinology, 1998, 23, 1-17.	2.7	168
417	Determination of Non-Protein-Bound Plasma 1,25-Dihydroxyvitamin D by Symmetric (Rate) Dialysis. Analytical Biochemistry, 1998, 258, 176-183.	2.4	17
418	Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay. , 1998, 77, 236-242.		29
419	ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts., 1997, 72, 416-423.		15
420	Kinetic analysis of rat steroid 5î±-reductase activity in prostate and epididymis homogenates at neutral pH: Evidence for type I activity in epididymis. Journal of Steroid Biochemistry and Molecular Biology, 1996, 57, 95-101.	2.5	8
421	3î±-Hydroxysteroid oxidoreductase activities in dihydrotestosterone degradation and back-formation in rat prostate and epididymis. Journal of Steroid Biochemistry and Molecular Biology, 1996, 58, 319-324.	2.5	16
422	Kinetic analysis of steroid 5α-reductase activity at neutral pH in benign prostatic hyperplastic tissue: Evidence for type I isozyme activity in the human prostate. Journal of Steroid Biochemistry and Molecular Biology, 1996, 57, 103-108.	2.5	32
423	Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 Workshop. European Journal of Cancer, 1996, 32, 1371-1381.	2.8	71
424	Effects of cytokines on pituitary \hat{l}^2 -endorphin and adrenal corticosterone release in vitro. Cytokine, 1996, 8, 238-247.	3.2	29
425	CHRONIC STIMULATION OF THE HYPOTHALAMUS–PITUITARY–ADRENAL AXIS IN RATS BY INTERLEUKIN 1β: CENTRAL AND PERIPHERAL MECHANISMS. Cytokine, 1996, 8, 910-919.	3.2	33
426	Differential subcellular distribution of rat prostatic steroid 5α-reductase isozyme activities. European Journal of Endocrinology, 1996, 134, 386-392.	3.7	8
427	Quality control in quantitation of components of the plasminogen activator system in tumour extracts. Fibrinolysis, 1996, 10, 149-151.	0.5	3
428	Rat steroid 5α-reductase kinetic characteristics: Extreme pH-dependency of the type II isozyme in prostate and epididymis homogenates. Journal of Steroid Biochemistry and Molecular Biology, 1995, 54, 185-192.	2.5	13
429	Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 2859-2865.	3.6	118
430	Different effects of continuous infusion of interleukin-1 and interleukin-6 on the hypothalamic-hypophysial-thyroid axis. Endocrinology, 1994, 135, 1336-1345.	2.8	23
431	Intravenous administration of interleukin- $1\hat{l}^2$ induces Fos-like immunoreactivity in corticotropin-releasing hormone neurons in the paraventricular hypothalamic nucleus of the rat. Journal of Chemical Neuroanatomy, 1993, 6, 391-397.	2.1	34
432	Chronic intraperitoneal infusion of low doses of tumor necrosis factor \hat{l}_{\pm} in rats induces a reduction in plasma triglyceride levels. Cytokine, 1992, 4, 561-567.	3.2	13

#	Article	IF	CITATIONS
433	Chronic stimulation of the pituitary-adrenal axis in rats by interleukin-1 beta infusion: in vivo and in vitro studies. Endocrinology, 1992, 130, 1153-1164.	2.8	44
434	Continuous infusion of interleukin-1 beta induces a nonthyroidal illness syndrome in the rat. Endocrinology, 1992, 131, 2139-2146.	2.8	27
435	The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). International Journal of Oncology, 1992, 32, 1145-1157.	3.3	40
436	Effects of Chronic Treatment of Rats with Dopamine Receptor Drugs on the Post-Translational Processing of Beta-Endorphin in the Neurointermediate Lobe of the Pituitary Gland. Journal of Neuroendocrinology, 1990, 2, 531-537.	2.6	4
437	Effects of Pituitary Beta-Endorphin Secretagogues on the Concentration of Beta-Endorphin in Rat Cerebrospinal Fluid: Evidence for a Role of Vasopressin in the Regulation of Brain Beta-Endorphin Release. Neuroendocrinology, 1990, 51, 104-110.	2.5	18
438	Effects of chronic treatment with haloperidol and bromocriptine on the processing of \hat{l}^2 -endorphin to \hat{l}^3 - and \hat{l}_2 -endorphin in discrete regions of the rat pituitary gland and brain. Neuropharmacology, 1990, 29, 61-68.	4.1	13
439	Isoproterenol-stimulated release of \hat{l}^2 -endorphin and related peptides from the rat pituitary neurointermediate lobe in vitro: Evidence for preferential release of certain molecular forms of \hat{l}^2 -endorphin. Neuropeptides, 1990, 17, 63-73.	2.2	9
440	Cytokines and the hypothalamic-pituitary-adrenal axis. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 867-871.	2.5	99
441	Release of \hat{I}^2 -endorphin-immunoreactivity from rat pituitary and hypothalamus in vitro: Effects of isoproterenol, dopamine, corticotropin-releasing factor and agrinine8-vasopressin. Biochemical and Biophysical Research Communications, 1989, 161, 221-228.	2.1	24
442	\hat{l}^2 -endorphin in brain limbic structures as neurochemical correlate of psychic dependence on drugs. Life Sciences, 1989, 44, 1133-1140.	4.3	58
443	Characterization of \hat{l}^2 -endorphin-immunoreactivity in limbic brain structures of rats self-administering heroin or cocaine. Neuropeptides, 1988, 12, 229-236.	2.2	31
444	Leu-Phe Cleaving Endopeptidase Activity, \hat{I}^3 -Endorphin, and \hat{I}^2 -Endorphin in the Rat Pituitary Gland and Brain. Neuroendocrinology, 1988, 47, 7-12.	2.5	9
445	Effect of acute administration of \hat{l} "1-tetrahydrocannabinol on \hat{l} 2-endorphin levels in plasma and brain tissue of the rat. Experientia, 1987, 43, 413-415.	1.2	6